 Novartis AG's expectations for a new heart-failure drug suffered a second setback as a Food and Drug Administration staff review recommended against approval. Earlier this year, an advisory panel in Europe made a similar recommendation.. The FDA's medical review said the data didn't show serelaxin slowed progress of heart failure nor did it "provide persuasive evidence of an effect" on shortness of breath, a main heart-failure symptom.